Volume 19, Issue 1, Pages (January 2017)

Slides:

Advertisements

Similar presentations

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Advertisements

Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model Jie Li, Ni Hou, Ahmad Faried, Soichi Tsutsumi,

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

Drug concentration (μM)

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

Volume 18, Issue 12, Pages (December 2016)

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Volume 24, Issue 5, Pages (November 2013)

Volume 145, Issue 2, Pages (August 2013)

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Molecular Therapy - Oncolytics

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis Dao M Nguyen, MD, Dominique.

Supplementary Figure S13

MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

IFN-γ Induces Gastric Cancer Cell Proliferation and Metastasis Through Upregulation of Integrin β3-Mediated NF-κB Signaling Yuan-Hua Xu, Zheng-Li Li,

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models Andrey.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Volume 5, Issue 3, Pages (March 2004)

Volume 19, Issue 7, Pages (July 2017)

The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death Kwang Woon Kim, PhD, Christina K. Speirs,

Volume 19, Issue 2, Pages (February 2017)

Volume 58, Issue 5, Pages (November 2000)

Volume 19, Issue 3, Pages (March 2017)

Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung Cancer Silvan Becker, MD, Boyka Markova, PhD, Rainer.

Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

Spying on cancer Cancer Cell

Volume 19, Issue 7, Pages (July 2017)

Volume 138, Issue 1, Pages (January 2010)

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models Josephine Hai, PhD, Shingo Sakashita,

Volume 19, Issue 9, Pages (September 2017)

Volume 139, Issue 6, Pages (December 2010)

Volume 145, Issue 2, Pages (August 2013)

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Cisplatin augments cytotoxic T-lymphocyte–mediated antitumor immunity in poorly immunogenic murine lung cancer Robert E Merritt, MD, Ali Mahtabifard,

Nicholas D. James, Jim W. Growcott European Urology Supplements

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Volume 27, Issue 1, Pages (January 2015)

miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK

Molecular Therapy - Nucleic Acids

Select Cancer Testes Antigens of the MAGE-A, -B, and -C Families Are Expressed in Mast Cell Lines and Promote Cell Viability In Vitro and In Vivo Bing.

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD, Michael.

Jae Won Chang, Daniel K. Nomura, Benjamin F. Cravatt

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Volume 15, Issue 3, Pages (March 2009)

In vivo efficacy of Olaparib in PTEN deficient xenografts.

Suppression of IGF1R in Melanoma Cells by an Adenovirus-Mediated One-Step Knockdown System Haoran Xin, Mingxing Lei, Zhihui Zhang, Jie Li, Hao Zhang,

Volume 17, Issue 2, Pages (February 2009)

In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone

Supplemental Figure 6 Supplemental Figure 6. Treatment with erlotinib plus TAS-115 inhibits the growth of PC-9/HGF tumors in vivo. (A, B) Nude mice bearing.

Volume 18, Issue 3, Pages (March 2010)

Activity of MAC-321 (i. v. and p. o

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Molecular Therapy - Nucleic Acids

Yoshinori Aragane, Akira Maeda, Chang-Yi Cui, Tadashi Tezuka

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer Jun Young Park, Ye Lim Cho, Ju Ri Chae, Sung Hwan Moon,

Antitumor effects of celastrol in vitro and in vivo.

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Non–Small- Cell Lung Cancer Cheng-Yi Wang, MD, Ting-Ting Chao, PhD, Wei-Tien.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Presentation transcript:

Volume 19, Issue 1, Pages 35-42 (January 2017) In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models Federica Guffanti, Rosaria Chilà, Ezia Bello, Massimo Zucchetti, Monique Zangarini, Laura Ceriani, Mariella Ferrari, Monica Lupi, Anne Jacquet-Bescond, Mike F. Burbridge, Marie-Jeanne Pierrat, Giovanna Damia Neoplasia Volume 19, Issue 1, Pages 35-42 (January 2017) DOI: 10.1016/j.neo.2016.11.008 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Lucitanib in vitro activity (IC50) in lung, endometrial and gastric cancer cell lines. wt FGFR1/2: (☐); amplified FGFR1:(Image 1); amplified FGFR2: (Image 2); mutated FGFR2: (Image 3). IC50 values have been calculated as described in Materials and Methods and are the arithmetic mean IC50 (μM)+SEM. Neoplasia 2017 19, 35-42DOI: (10.1016/j.neo.2016.11.008) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Cell cycle perturbation and apoptosis induced by lucitanib treatment. A. Flow cytometric analysis of DNA content during treatment with IC50 lucitanib dose in H1299 cells (right panel, 10 μM) and DMS114 cells (left panel, 1 μM). Upper panels show the DNA content of untreated cells (“ctrl”), while lower panels show the DNA content of cells treated with IC50 lucitanib dose for 4, 24, 48 and 72 hours. B. Flow cytometric analysis of apoptotic cells represented by biparametric PI fluorescence (DNA content) and dUTP-FITC fluorescence. Untreated and treated cells are represented as in Panel A at the same times and doses of treatment. Cells with DNA fragmentation induced during apoptosis are dUTP-positive (above the straight line). DNA corresponding to G1 (2 N) and G2 M (4 N) cells is indicated. Neoplasia 2017 19, 35-42DOI: (10.1016/j.neo.2016.11.008) Copyright © 2016 The Authors Terms and Conditions

Figure 3 Lucitanib in vivo antitumor activity in aberrant and wt FGFR1 or FGFR2 lung, endometrial and gastric cancer xenografts. A Inhibition of the growth of lung tumor xenografts (upper panel: H1299 tumor xenograft (NSCLC FGFR1 wt), middle panel: H1581 tumor xenograft (NSCLC FGFR1 amplified), lower panel: DSM114 xenograft (SCLC FGFR1 amplified); B Inhibition of the growth of endometrial tumor xenografts (upper panel: HEC1A FGFR2 wt; lower panel: MFE296 (FGFR2 N550 K); C. Inhibition of the growth of gastric tumor xenografts (upper panel: MNK45 FGFR2 wt; lower panel: SNU16 FGFR2 amplified). The different xenografts were subcutaneously transplanted into nude mice as described in Material and Methods. When tumor volumes reached 200–250 mm3, mice were randomized to receive vehicle (□) or 2.5 (■), 5 (▲), 10 (●) and 20 (*) mg/kg lucitanib doses administered orally, daily for 30 days. Arithmetic mean tumor volumes (+/− SEM) of 8–10 animals per group are shown. Neoplasia 2017 19, 35-42DOI: (10.1016/j.neo.2016.11.008) Copyright © 2016 The Authors Terms and Conditions

Figure 4 Lucitanib plasma (A) and tumor (B) concentrations in lung xenografts. The different xenografts were subcutaneously transplanted into nude mice and when tumor volumes reached 300–400 mg, mice were daily treated for 12 days at the indicated doses. 4 hours (right panels A and B) and 24 hours (left panels A and B) after the last drug administration, animals were sacrificed and plasma and tumors taken. Drug levels were determined as specified in Materials and Methods. The mean of lucitanib concentration+SD of four different animals are shown, for mice bearing H1299 (☐); H1581 (Image 4); DMS114 (Image 5) xenografts, respectively. Neoplasia 2017 19, 35-42DOI: (10.1016/j.neo.2016.11.008) Copyright © 2016 The Authors Terms and Conditions